• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.

作者信息

Hofling A Alex, Fotenos Anthony F, Niu Gang, Fallah Jaleh, Agrawal Sundeep, Wang Sue-Jane, Marzella Libero

机构信息

Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland;

Division of Imaging and Radiation Medicine, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.

出版信息

J Nucl Med. 2022 Nov;63(11):1642-1643. doi: 10.2967/jnumed.122.264299. Epub 2022 Jul 7.

DOI:10.2967/jnumed.122.264299
PMID:35798555
Abstract
摘要

相似文献

1
Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.前列腺癌诊疗一体化：美国食品药品监督管理局对首款用于为配对放射性配体治疗药物选择患者的诊断成像药物的同步批准。
J Nucl Med. 2022 Nov;63(11):1642-1643. doi: 10.2967/jnumed.122.264299. Epub 2022 Jul 7.
2
Theranostics of Metastatic Prostate Cancer Applying Cu/F/Ga PSMA PET-CT and Lu Radiopharmaceuticals.转移性前列腺癌的治疗应用：Cu/F/Ga PSMA PET-CT 和 Lu 放射性药物。
Curr Radiopharm. 2021;14(4):354-358. doi: 10.2174/1874471013666200908122845.
3
[PSMA-based theranostics for prostate cancer : From imaging to treatment].[基于前列腺特异性膜抗原的前列腺癌诊疗一体化：从成像到治疗]
Urologe A. 2020 May;59(5):617-625. doi: 10.1007/s00120-020-01193-x.
4
Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective.双示踪剂 PET-计算机断层扫描成像在前列腺癌精准放化疗中的应用：未来展望。
PET Clin. 2022 Oct;17(4):641-652. doi: 10.1016/j.cpet.2022.07.008. Epub 2022 Sep 22.
5
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.一项前瞻性随机多中心研究，评估镓-68 前列腺特异性膜抗原（PSMA）PET/CT 成像在根治性手术或放疗前对高危前列腺癌分期的影响（proPSMA 研究）：临床试验方案。
BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3.
6
The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.PSMA PET 成像在前列腺癌治疗学中的作用：一项全国性调查。
Urol Int. 2022;106(11):1126-1135. doi: 10.1159/000526598. Epub 2022 Oct 4.
7
Ga-DOTA-RGD Positron Emission Tomography/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with F-FDG Positron Emission Tomography/Computed Tomography and Evaluation Toward Potential Theranostics.镓-DOTA-RGD 正电子发射断层扫描/计算机断层扫描在放射性碘难治性甲状腺癌中的应用：与 F-FDG 正电子发射断层扫描/计算机断层扫描的诊断准确性的前瞻性比较及潜在治疗学评估。
Thyroid. 2020 Apr;30(4):557-567. doi: 10.1089/thy.2019.0450. Epub 2020 Jan 23.
8
Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen.前列腺癌影像学诊断：前列腺特异性膜抗原的临床应用价值。
J Urol. 2022 Apr;207(4):769-778. doi: 10.1097/JU.0000000000002457. Epub 2022 Jan 27.
9
[Oncological theranostics in nuclear medicine].[核医学中的肿瘤诊疗一体化]
Radiologie (Heidelb). 2022 Oct;62(10):875-884. doi: 10.1007/s00117-022-01072-w.
10
PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.PSMA 治疗学：每个前列腺癌中心的“必备”。两个临床病例的说明和文献复习。
Clin Genitourin Cancer. 2021 Aug;19(4):e235-e247. doi: 10.1016/j.clgc.2021.03.008. Epub 2021 Mar 17.

引用本文的文献

1
EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment.用于增强胰腺癌治疗的 EphA2 靶向α粒子诊疗技术
Theranostics. 2025 Mar 18;15(10):4229-4246. doi: 10.7150/thno.106948. eCollection 2025.
2
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.肽-药物偶联物：作为一种新型癌症诊疗手段的设计、化学及药物递送系统
ACS Pharmacol Transl Sci. 2024 Jan 24;7(2):309-334. doi: 10.1021/acsptsci.3c00269. eCollection 2024 Feb 9.
3
A prospective head-to-head comparison of [Ga]Ga-P16-093 and [Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer.
原发性前列腺癌患者中 [Ga]Ga-P16-093 与 [Ga]Ga-PSMA-11 PET/CT 的前瞻性头对头比较。
Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):3126-3136. doi: 10.1007/s00259-023-06283-4. Epub 2023 May 26.
4
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.美国食品药品监督管理局批准概要：镥 177 标记的维泊妥组单抗用于治疗转移性去势抵抗性前列腺癌患者。
Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875.
5
From Concept to Regulatory Drug Approval: Lessons for Theranostics.从概念到药物监管批准：诊疗一体化的经验教训
J Nucl Med. 2022 Dec;63(12):1793-1801. doi: 10.2967/jnumed.121.263301.
6
Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.从抗体药物偶联物中学习：未来构建用于癌症治疗的肽-药物偶联物时的考量。
Exp Hematol Oncol. 2022 Nov 8;11(1):93. doi: 10.1186/s40164-022-00347-1.